<DOC>
	<DOCNO>NCT00814307</DOCNO>
	<brief_summary>This Phase 3 study intend provide evidence efficacy safety CP 690,550 dose 5 mg 10 mg twice day monotherapy adult patient moderate severe Rheumatoid Arthritis . It intend confirm benefit CP-690,550 improve sign symptom physical function observe Phase 2 Rheumatoid Arthritis study .</brief_summary>
	<brief_title>A Phase 3 Study Comparing 2 Doses CP-690,550 v . Placebo Treatment Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>The patient diagnosis RA base upon American College Rheumatology ( ACR ) 1987 Revised Criteria . The patient active disease Screening Baseline , define : ≥6 joint tender painful motion ; ≥6 joint swell ; fulfills 1 follow 2 criterion Screening : 1.ESR ( Westergren method ) &gt; 28 mm local laboratory . 2 . CRP &gt; 7 mg/L central laboratory Patient inadequate response least one DMARD ( traditional biologic ) due lack efficacy toxicity . No evidence active latent inadequately treated infection Mycobacterium tuberculosis . Patient wash DMARDs antimalarial Blood dyscrasia include confirm : 1 . Hemoglobin &lt; 9 g/dL Hematocrit &lt; 30 % ; 2 . White blood cell count &lt; 3.0 x 109/L ; 3 . Absolute neutrophil count &lt; 1.2 x 109/L ; 4 . Platelet count &lt; 100 x 109/L History autoimmune rheumatic disease Sjogren 's syndrome No malignancy history malignancy . History infection require hospitalization , parenteral antimicrobial therapy , otherwise judge clinically significant investigator , within 6 month prior first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Antirheumatic Agents Clinical Trial</keyword>
</DOC>